Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23, Pneumococcal Vaccine, Polyvalent, PNEUMOVAX 23
Pneumococcal Vaccine, Polyvalent · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Pneumococcal Vaccine, Polyvalent (23-valent) | EXPERIMENTAL | Participants received one 0.5 mL dose of Pneumococcal Vaccine, Polyvalent (23-valent) by intramuscular (deltoid) injection on Day 1. |
| Name | Type | Description |
|---|---|---|
| Pneumococcal Vaccine, Polyvalent (23-valent) | BIOLOGICAL | - |
Inclusion Criteria: * Healthy indian adults of 50 years of age * In good health; any underlying chronic illness must be documented to be in stable condition * Signed and dated informed consent prior to receipt of the study vaccine Exclusion Criteria: * Functional or anatomic asplenia * History of...
Pneumococcal Vaccine, Polyvalent is used to prevent pneumococcal infection. It is a vaccine developed by Merck & Company, Inc. (MRK) and is in Phase 3 clinical development. The vaccine is designed to protect against infections caused by Streptococcus pneumoniae bacteria.
Pneumococcal Vaccine, Polyvalent is made by Merck & Company, Inc., which trades under the ticker symbol MRK. Merck is the developer of this vaccine, which is also known as PNEUMOVAX 23.
Pneumococcal Vaccine, Polyvalent is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by the FDA. The only listed trial for this vaccine is a completed Phase 3 study.
Pneumococcal Vaccine, Polyvalent has been studied in one completed Phase 3 clinical trial, NCT00496093, titled "Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)." This trial enrolled 133 healthy adults aged 50 years and older and is now completed.
Yes, Pneumococcal Vaccine, Polyvalent is also known as PNEUMOVAX 23 or PNEUMOVAX™ 23. Other names include Pneumococcal Vaccine, Polyvalent (23-valent). These names refer to the same vaccine developed by Merck & Company, Inc. for the prevention of pneumococcal infection.